Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin, Gemcitabine, and Berzosertib in Recurrent Platinum-Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer
NCT02627443Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2017
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of berzosertib in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by National Cancer Institute. Primary endpoints: Dose Limiting Toxicity at 28 days and Incidence of Adverse Events at 3 years. Started May 2017; status: active, not recruiting.
02
Drugs
berzosertib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT02627443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02627443.